Catalyst Calendar

Wed, Sep 30, 2026

1 updates

8:30 AM

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agent BEDFORD, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the

lantheus.com

Mon, Sep 28, 2026

1 updates

LNTH

8:00 AM

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer BEDFORD, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to

Trial Start • Phase 2/3Trial initiation Mon, Sep 28, 2026lantheus.com

Tue, Sep 22, 2026

1 updates

LNTH

8:00 AM

Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs

Approval of BRAVNETSA expands radioligand treatment options for adult patients with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.

lantheus.com